Dashboard
1
Poor Management Efficiency with a low ROCE of 1.04%
- The company has been able to generate a Return on Capital Employed (avg) of 1.04% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 0.78% and Operating profit at -252.79% over the last 5 years
4
The company has declared Negative results for the last 9 consecutive quarters
5
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,990 Million (Small Cap)
NA (Loss Making)
NA
0.00%
0.99
-52.59%
3.65
Revenue and Profits:
Net Sales:
112 Million
(Quarterly Results - Jun 2026)
Net Profit:
-17 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.58%
0%
-12.58%
6 Months
38.62%
0%
38.62%
1 Year
64.08%
0%
64.08%
2 Years
219.13%
0%
219.13%
3 Years
100.77%
0%
100.77%
4 Years
82.43%
0%
82.43%
5 Years
108.32%
0%
108.32%
Shaanxi Kanghui Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.78%
EBIT Growth (5y)
-252.79%
EBIT to Interest (avg)
-3.03
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.66
Sales to Capital Employed (avg)
0.39
Tax Ratio
1.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.28%
ROE (avg)
1.20%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.57
EV to EBIT
-15.43
EV to EBITDA
-18.38
EV to Capital Employed
4.31
EV to Sales
10.54
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-27.93%
ROE (Latest)
-52.59%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
112.00
93.40
19.91%
Operating Profit (PBDIT) excl Other Income
9.50
4.00
137.50%
Interest
6.80
7.60
-10.53%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-16.70
21.90
-176.26%
Operating Profit Margin (Excl OI)
-73.20%
-147.40%
7.42%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 19.91% vs -18.85% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is -176.26% vs 112.20% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
469.40
559.10
-16.04%
Operating Profit (PBDIT) excl Other Income
-79.80
-7.10
-1,023.94%
Interest
35.10
35.10
Exceptional Items
-165.20
2.50
-6,708.00%
Consolidate Net Profit
-336.30
-112.00
-200.27%
Operating Profit Margin (Excl OI)
-305.60%
-116.00%
-18.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -16.04% vs -16.76% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -200.27% vs -120.47% in Dec 2024
About Shaanxi Kanghui Pharmaceutical Co., Ltd. 
Shaanxi Kanghui Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






